Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended		80 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating expenses:
Research and development	$ 78,731	$ 337,003	$ 320,558	$ 847,298	$ 16,312,087
General and administrative	406,862	140,746	700,489	493,210	4,005,022
Purchase of in-process research and development					650,000
Total operating expenses	485,593	477,749	1,021,047	1,340,508	20,967,109
Loss from operations	(485,593)	(477,749)	(1,021,047)	(1,340,508)	(20,967,109)
Other income (expense)
Interest income	629	466	2,850	1,401	216,702
Interest expense	(39,940)	(10,521)	(119,570)	(10,521)	(325,512)
Change in fair value of preferred stock purchase right					(188,587)
Change in fair value of warrant liability	39,000	1,550	(82,000)	4,550	(54,264)
Grant income					244,000
Total other income (expense)	(311)	(8,505)	(198,720)	(4,570)	(107,661)
Net loss and comprehensive loss	$ (485,904)	$ (486,254)	$ (1,219,767)	$ (1,345,078)	$ (21,074,770)
Net loss per common share, basic and diluted	$ (0.41)	$ (0.43)	$ (1.06)	$ (1.20)
Weighted-average shares used to compute basic and diluted net loss per share	1,190,212	1,125,875	1,153,751	1,122,125